Biotech stock Neurogene collapsed Tuesday after a patient experienced a serious side effect in the company's Rett syndrome ...

In a bid to streamline viral vector manufacturing, Thermo Fisher is charting another round of layoffs this year—and ...

New data publishing 11/11 in Cell Stem Cell provides strong support for the first-in-human universal gene therapy trial for ...

A research team has established a virus-induced gene silencing (VIGS) system in taro, enabling researchers to rapidly verify ...

Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...

The gene therapy improved annualized bleed rates, though a handful of study participants resumed factor IX prophylaxis.

Its lead gene therapy candidate has the potential to be faster, less expensive, and more widely available than current CAR T ...

ATA-200 is a one-time gene therapy for the treatment of γ-sarcoglycan related ... a single-dose Adeno-Associated Virus (AAV) vector carrying the human γ-sarcoglycan transgene. The deployment in the US ...

Marcel Imwinkelried, Chief Executive Officer Siegfried: “Aligned with Siegfried's strategy EVOLVE+, the new lab facility marks a key milestone in DINAMIQS' journey to becoming the leading CDMO in the ...

Cardiovascular disease remains the foremost cause of morbidity and mortality globally, affecting millions of individuals. Recent discoveries illuminate the substantial role of genetics in ...